Chordate Medical will be granted a fourth patent in the US for the migraine treatment Ozilia. In parallel, work is underway to obtain market approval from the FDA.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0632 SEK | -15.73% |
|
+17.04% | -60.60% |
13/06 | Chordate Medical Holding AB Enters New Partnership Agreement with Neurolite AG | CI |
13/06 | Chordate Medical Holding AB (OM:CMH) signed an agreement to acquire Neurolite. | CI |
1st Jan change | Capi. | |
---|---|---|
-60.60% | 3.46M | |
+3.77% | 213B | |
+8.83% | 188B | |
+31.94% | 157B | |
+33.19% | 113B | |
+5.25% | 64.85B | |
+22.41% | 55.17B | |
+1.34% | 49.1B | |
-5.92% | 38.83B | |
+1.94% | 35.6B |
- Stock Market
- Equities
- CMH Stock
- News Chordate Medical Holding AB
- Chordate Medical Receives Patent Approval in the US